Research Article
The Impact of Race in Male Breast Cancer Treatment and Outcome in the United States: A Population-Based Analysis of 4,279 Patients
Table 4
Five-year Kaplan-Meier disease-specific survival by race.
| | | Total | White | Black | Hispanic | Asian | Log-rank value |
| | Overall | 87.5% (±0.7) | 88.6% (±0.7) | 80.0% (±2.3) | 86.6% (±3.0) | 90.2% (±2.8) | < 0.001 | | Age | | | | | | = 0.970 | | 65 years | 88.9% (±0.9) | 90.0% (±1.0) | 84.7% (±2.6) | 85.6% (±4.0) | 88.6% (±4.0) | = 0.002 | | 65 years | 86.2% (±1.0) | 87.4% (±1.0) | 71.6% (±4.3) | 83.6% (±5.4) | 92.1% (±3.8) | < 0.001 | | Year of diagnosis | | | | | | = 0.215 | | 1988–1993 | 86.6% (±1.7) | 87.1% (±1.9) | 81.4% (±6.0) | 87.5% (±8.3) | 88.0% (±6.5) | = 0.683 | | 1994–1999 | 86.8% (±1.4) | 90.5% (±1.3) | 66.8% (±5.6) | 74.8% (±8.3) | 87.5% (±5.8) | < 0.001 | | 2000–2005 | 88.1% (±0.9) | 88.3% (±1.0) | 84.6% (±2.6) | 90.4% (±3.2) | 92.8% (±3.5) | = 0.056 | | Marital status | | | | | | < 0.001 | | Single | 80.9% (±2.3) | 82.7% (±2.7) | 74.3% (±5.4) | 83.5% (±7.6) | 85.7% (±13.2) | = 0.546 | | Married | 90.2% (±0.7) | 90.9% (±0.8) | 85.3% (±2.7) | 84.1% (±4.0) | 92.4% (±2.8) | = 0.005 | | Separated | 54.5% (±10.7) | 61.1% (±15.4) | 44.4% (±16.6) | 50.0% (±35.4) | — | = 0.475 | | Divorced | 81.8% (±3.0) | 82.6% (±3.4) | 81.1% (±7.0) | 88.9% (±10.5) | 33.3% (±27.2) | = 0.086 | | Widowed | 81.9% (±3.0) | 83.4% (±3.2) | 64.7% (±11.1) | 100.0% (±0.0) | 85.7% (±13.2) | = 0.046 | | Unknown | 85.3% (±3.9) | 84.1% (±4.6) | 85.7% (±9.4) | — | 100.0% (±0.0) | = 0.351 | | Histology | | | | | | < 0.001 | | In situ | 99.3% (±0.5) | 99.1% (±0.6) | 100.0% (±0.0) | 100.0% (±0.0) | 100.0% (±0.0) | = 0.874 | | Ductal | 85.5% (±0.8) | 86.8% (±0.9) | 75.9% (±2.8) | 82.8% (±3.8) | 89.7% (±3.3) | < 0.001 | | Papillary | 92.9% (±4.0) | 93.3% (±4.6) | 100.0% (±0.0) | — | 50.0% (±35.4) | = 0.136 | | Mucinous | 94.3% (±3.2) | 96.9% (±3.1) | 87.5% (±8.3) | 100.0% (±0.0) | — | = 0.744 | | Medullary | 100.0% (±0.0) | 100.0% (±0.0) | — | — | 100.0% (±0.0) | — | | Lobular | 88.9% (±3.7) | 89.4% (±4.1) | 80.0% (±17.9) | 50.0% (±25.0) | 80.0% (±17.9) | = 0.167 | | ER/PR status | | | | | | < 0.001 | | ER−/PR− | 85.0% (±3.4) | 83.6% (±4.2) | 89.7% (±6.9) | 71.4% (±17.1) | 100.0% (±0.0) | = 0.359 | | ER+/PR− | 77.6% (±2.8) | 80.7% (±3.0) | 71.4% (±7.7) | 55.6% (±16.6) | 57.1% (±18.7) | = 0.082 | | ER+/PR+ | 88.0% (±0.9) | 88.7% (±1.0) | 78.8% (±3.5) | 89.1% (±3.9) | 95.3% (±2.6) | < 0.001 | | Unknown | 89.7% (±1.1) | 91.4% (±1.2) | 82.2% (±3.5) | 91.2% (±4.2) | 84.8% (±6.3) | = 0.008 | | Treatment | | | | | | < 0.001 | | None | 61.4% (±5.4) | 68.2% (±6.5) | 42.9% (±11.4) | 80.0% (±17.9) | 41.7% (±22.2) | = 0.131 | | Primary RT | 40.2% (±7.9) | 36.2% (±9.0) | 53.6% (±20.1) | 50.0% (±25.0) | — | = 0.823 | | Partial mast. | 92.8% (±1.7) | 91.4% (±2.1) | 93.8% (±4.3) | 100.0% (±0.0) | 100.0% (±0.0) | = 0.673 | | Nipple-sparing mast. | 100.0% (±0.0) | 100.0% (±0.0) | — | — | — | — | | Simple mast. | 92.0% (±1.3) | 92.5% (±1.4) | 87.9% (±4.6) | 95.8% (±4.1) | 89.2% (±7.2) | = 0.346 | | Modified rad. mast. | 88.1% (±0.8) | 89.4% (±0.9) | 80.1% (±2.9) | 84.2% (±4.0) | 91.2% (±3.4) | < 0.001 | | Rad. mast. | 72.6% (±8.8) | 72.2% (±10.6) | 71.4% (±17.1) | — | — | = 0.736 | | Surgery, NOS | 85.7% (±9.4) | 81.8% (±11.6) | — | — | 81.8% (±11.6) | = 0.711 | | LNDX | | | | | | < 0.001 | | No | 78.7% (±2.0) | 79.7% (±2.3) | 69.6% (±5.7) | 91.0% (±6.1) | 78.0% (±9.8) | = 0.045 | | Yes | 89.3% (±0.7) | 90.4% (±0.7) | 82.6% (±2.4) | 85.7% (±3.4) | 92.6% (±2.7) | < 0.001 | | Adjuvant RT | | | | | | < 0.001 | | No | 89.2% (±0.7) | 90.7% (±0.8) | 80.9% (±2.5) | 88.4% (±3.3) | 87.7% (±3.5) | < 0.001 | | Yes | 85.2% (±1.6) | 85.0% (±1.8) | 79.1% (±5.2) | 85.2% (±6.8) | 100.0% (±0.0) | = 0.019 | | Nodal metastases | | | | | | < 0.001 | | No | 91.4% (±0.7) | 91.9% (±0.8) | 88.0% (±2.3) | 93.7% (±2.7) | 90.3% (±3.5) | = 0.006 | | Yes | 80.4% (±1.4) | 82.7% (±1.5) | 66.4% (±4.5) | 73.5% (±6.6) | 90.1% (±4.7) | < 0.001 | | Stage | | | | | | < 0.001 | | 0 | 99.3% (±0.5) | 99.1% (±0.6) | 100.0% (±0.0) | 100.0% (±0.0) | 100.0% (±0.0) | = 0.874 | | I | 97.5% (±0.6) | 97.7% (±0.6) | 98.8% (±1.2) | 91.2% (±4.8) | 97.4% (±2.6) | = 0.285 | | II | 89.8% (±1.0) | 90.1% (±1.1) | 84.6% (±3.6) | 95.2% (±3.3) | 93.2% (±3.8) | = 0.012 | | III | 70.5% (±2.4) | 75.8% (±2.6) | 48.5% (±6.7) | 65.1% (±9.5) | 67.1% (±13.5) | < 0.001 | | IV | 24.7% (±4.1) | 21.7% (±4.6) | 38.4% (±10.0) | 28.6% (±17.1) | — | = 0.460 | | Grade | | | | | | < 0.001 | | 1 | 96.3% (±1.1) | 97.7% (±1.0) | 85.0% (±6.2) | 100.0% (±0.0) | 100% (±0.0) | = 0.024 | | 2 | 90.4% (±0.9) | 91.1% (±1.0) | 82.8% (±3.5) | 91.8% (±3.9) | 95.9% (±2.8) | < 0.001 | | 3 | 79.9% (±1.4) | 80.9% (±1.6) | 71.5% (±4.7) | 73.8% (±6.8) | 87.9% (±5.7) | = 0.034 | | Unknown | 88.6% (±1.6) | 90.8% (±1.6) | 84.7% (±4.5) | 82.7% (±7.9) | 70.6% (±11.1) | = 0.338 |
|
|
